Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease
Alzheimer’s Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of amyloid beta1-40 and 1-42, and intracellular neurofibrillary tangles (NFTs). For decades, neuroscien...
Saved in:
| Main Authors: | Xiaoming Qi, Damir Nizamutdinov, Song Stephen Yi, Erxi Wu, Jason H. Huang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/11/2636 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancements in Alzheimer's Disease Therapy: The Role of Anti-Amyloid Monoclonal Antibodies - A Literature Review
by: Agnieszka Skoczeń, et al.
Published: (2025-03-01) -
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
by: Byeong-Hyeon Kim, et al.
Published: (2025-01-01) -
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
by: Taha basit Ameen, et al.
Published: (2025-05-01) -
Anti-amyloid Monoclonal Antibodies for Alzheimer’s Disease: A New Hope? (Review)
by: I. A. Mazerkina
Published: (2025-04-01) -
Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease
by: Ricardo Nitrini, et al.
Published: (2025-05-01)